Evaluation and monitoring of response to platelet transfusion therapy: experience from a tertiary care center

References

• Estcourt LJ, Birchall J, Lowe D, et al. Platelet transfusions in haematology patients: are we using them appropriately? Vox Sang. 2012;103:284–293.
   Google Scholar
• Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105:4106–4114.
   Google Scholar
• Bishop JF, Matthews JP, McGrath K, et al. Factors influencing 20-hour increments after platelet transfusion. Transfusion. 1991;31:392–396.
   Google Scholar
• Bishop JF, Matthews JP, Yuen K, et al. The definition of refractoriness to platelet transfusions. Transfus Med. 1992;2:35–41.
   Google Scholar
• Doughty HA, Murphy MF, Metcalfe P, et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang. 1994;66:200–205.
   Google Scholar
• Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142:348–360.
   Google Scholar
• British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122:10–23.
   Google Scholar
• Saran RK. Blood component preparation and uses. 2nd ed. Transfus. Med. Tech. Man. New Delhi: Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; 2003.
   Google Scholar
• Kaufman RM, Shehata N. Hemotherapy and decision outcomes. In: Fung MK, editor. Bethesda, Maryland, US: AABB technical manual. 19th ed. AABB Press; 2017. p. 505–526.
   Google Scholar
• Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162:205.
   Google Scholar
• Michael F, Murphy SJSLE. Thrombocytopenia and platelet transfusion. In: Simon T, McColloug J, Snyder ELSBS, editors. Ross principles transfusion medicine. 5th ed. West Sussex, UK: John Wiley & Sons; 2016. p. 235–244.
   Google Scholar
• Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
   Google Scholar
• McFarland JG. Detection and identification of platelet antibodies in clinical disorders. Transfus Apher Sci. 2003;28:297–305.
   Google Scholar
• Schwartz KA. Platelet antibody: review of detection methods. Am J Hematol. 1988;29:106–114.
   Google Scholar
• Mangwana S, Simon N. Evaluation of the platelet cross-matching in oncology patients. Glob J Transfus Med. 2016;1:16.
   Google Scholar
• Agarwal N, Chatterjee K, Kumar P, et al. Prevalence of platelet reactive antibodies in patient′s refractory to platelet transfusions. Asian J Transfus Sci. 2014;8:126.
   Google Scholar
• Shastry S, Chaudhary R. Clinical factors influencing corrected count increment. Transfus Apher Sci. 2012;47:327–330.
   Google Scholar
• Kumawat V, Sharma RR, Malhotra P, et al. Prevalence of risk factors for platelet transfusion refractoriness in multitransfused hemato-oncological patients at tertiary care center in North India. Asian J Transfus Sci. 2015;9:61–64.
   Google Scholar
• Fabris F, Soini B, Sartori R, et al. Clinical and laboratory factors that affect the post-transfusion platelet increment. Transfus Sci. 2000;23:63–68.
   Google Scholar
• Hogge DE, Dutcher JP, Aisner J, et al. Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol. 1983;14:363–369.
   Google Scholar
• Daly PA, Schiffer CA, Aisner J, et al. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. J Am Med Assoc. 1980;243:435–438.
   Google Scholar
• Alcorta I, Pereira A, Ordinas A. Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study. Br J Haematol. 1996;93:220–224.
   Google Scholar
• Kiefel V, Konig C, Kroll H, et al. Platelet alloantibodies in transfused patients. Transfusion. 2001;41:766–770.
   Google Scholar
• Hussein MA, Lee EJ, Schiffer CA. Platelet transfusions administered to patients with splenomegaly. Transfusion. 1990;30:508–510.
   Google Scholar